Tomorrow is Grown here
Doing things differently since 1999.
The story of Medicago is rooted in a long track record of innovation and perseverance. Even our company name – the Latin word for alfalfa, which was the first plant we worked with – embodies our culture of adaptation. We're proud of our humble beginnings as much as we are of our current growth and global reach. We understand better than most that the path to success in not a straight line.
As a pioneer of plant-based transient expression and manufacturing, Medicago has always sought a more effective way to improve human health. With nearly 20 years of experience and wisdom behind us, we are ready to disrupt the traditional approach to vaccines and therapeutics.
Medicago has been privately held since 2013.
Here is a quick look at some of the key events and milestones that have helped shape the company as we exist today.
Medicago successfully produced a Virus-Like Particles (VLP) of the coronavirus in just 20 days and initiated Phase 1 in July.
Medicago announces the results of a Phase 3 efficacy study of its seasonal flu vaccine candidate.
Groundbreaking ceremony of the new Quebec City factory.
Medicago announces the start of a Phase 3 efficacy study.
Announcement of a major investment: Medicago will build a fully integrated manufacturing factory in Quebec City.
Mandate of the Public Health Agency of Canada (PHAC): Production of Ebola Virus Antibodies for the Sudan Strain.
Mitsubishi Tanabe Pharmaceutical Corp. becomes majority shareholder of Medicago and the company (MDG) is de-listed from the Toronto Stock Exchange (TSX)
Rapid fire test to produce more than 10M doses of H1N1 VLP vaccine in one month through a partnership with U.S. DARPA
Single dose of H5N1 VLP vaccine shows cross-protection against H5 and H2 strains
Medicago builds a GMP manufacturing plant in Durham, North Carolina with the creation of Medicago USA
Medicago announces production of the H1N1 Pandemic candidate vaccine 19 days after publication of the virus genetic sequence
Medicago's Initial Public Offering (IPO)
Development of new transient expression technologies with Nicotiana benthamiana.
Andy Sheldon joins as CEO, builds management team and changes the company business model to R&D pharmaceutical biotech focusing on vaccines & therapeutic proteins
Medicago incorporates after out-licensing the technology from Laval University and Agriculture Canada
Partnership between Agriculture Canada and Laval University
The President and Chief Executive Officer
President and Chief Executive Officer
Takashi Nagao joined Medicago as President and CEO in December 2020. He served as Medicago's Board of Directors since 2017 and as a Chairman since 2018, prior to his appointment, developing a deep understanding of the company's strategic objectives and core competencies. Takashi is a proven leader in health innovation and the pharmaceutical space. He has led businesses through periods of accelerated growth and innovation, relying on his extensive knowledge of drug development and commercialization, business development and finance, and corporate management.
Previously, Takashi led the development of Mitsubishi Tanabe's presence in the US, holding leadership positions at MTPC Holdings Canada, Mitsubishi Tanabe Pharma Development America, MP Healthcare Venture Management, and Mitsubishi Tanabe Pharma America. In these roles, Takashi oversaw the early stage venture investment, translational research, clinical development, medical affairs, regulatory affairs, drug safety, supply management, quality assurance, marketing, managed market, legal and compliance, human resources and more.
OUR EXECUTIVE COMMITTEE
We're proud to count some of the industry's finest among our ranks.
Chief Operating Officer
Carolyn brings a vast amount of expertise in drugs and biologic development, regulatory affairs, quality, pharmacovigilance, clinical development, medical writing, manufacturing and commercialization – key assets to transition our organization to the next step toward the commercialization of our first product. Carolyn's leadership will be crucial for the future success of Medicago.
Carolyn's responsibilities will be the day-to-day administration and operation of Medicago. She will sit on the Executive Committee and run the newly created Operating Committee.
Before joining Medicago, she held various positions including:
- VP Regulatory Affairs, Karyopharm
- Head of Commercial, Kinapse
- SVP Regulatory Affairs, inVentiv Health
- VP, Global Regulatory Affairs, Catalent Pharma Solutions
- Senior Director, International Regulatory Affairs, MedImmune,
- VP, Global Product Development Strategy and VP North America Consulting, PAREXEL International
- VP Regulatory Affairs at Celsion CorporationVP Preclinical Development at TherImmune Research Corporation
- VP Drug Development at GeminX Biotechnologies
- Director of Preclinical Development at ConjuChem and Manager of Preclinical
- Development at BioChem Pharma.
Carolyn holds a M.Sc. Chemistry from the University of Toronto, Canada and has a B.Sc. Chemistry from the University of Ottawa, Canada. She has worked in academic research at Stanford University, Toronto General Hospital and Chiba University, Japan, prior to her industry managerial appointments.
She currently serves as an Adjunct Professor at Georgetown University, lecturing the Master's Program in Clinical and Translational Research, and Course Director for the Pharmaceutical Education and Research Institute (PERI), as well as, Stanford and UCSF Center for Excellence in Regulatory Sciences, and previous contributor to the UCSF American Course of Drug Development and Regulatory Sciences (ACDRS).
Carolyn has co-authored 1 book chapter on First-in-Man global regulatory requirements, over 18 abstracts and 12 papers for industry associations and scientific publications and chaired DIA sessions (global regulatory) at the annual meetings. She has received numerous awards and scholarships throughout her career.
Chief Financial Officer
Mike Wanner is Medicago's Chief Financial Officer, and is responsible for developing the financial strategies of the company and for corporate governance. He also serves as executive lead of the IT function and strategies. He was previously President and CEO of Abeome, a biotechnology company developing therapeutic and diagnostic monoclonal antibodies and CEO for Oncose and ProLinia in Athens, GA. Prior to those positions, Mike served for over 11 years as CFO for Merial and Rhône Mérieux, Inc. (RMI), one of the world's leading animal health companies, where he was involved in the construction and management of a large-scale vaccine production facility in the U.S.
Executive Vice President, Scientific and Medical Affairs
Nathalie Landry is a dynamic biotech leader with more than 25 years of experience leading teams and programs to successful milestones. At Medicago, she oversees a multidisciplinary team in charge of R&D, preclinical and clinical development, clinical immunology, as well as scientific and medical affairs. Nathalie represents Medicago at numerous international conferences and meetings and is the co-author of several scientific publications and patents. She joined Medicago in 2000 as Director of Strategic Development and later became Senior Director of Product Development. In 2007, she was named Vice President.
Prior to joining Medicago she worked for a start-up biotech company developing and producing anticancer compounds, where she held various positions. Nathalie earned a Master's degree in microbiology-immunology in 1989 and an MBA in 1997, both from Laval University.
Chief Human Resources Officer
Lorrie Deyelle has been transforming the way human resource groups develop, build and measure business value for over 30 years. As Chief Human Resources Officer at Medicago, Lorrie is the leader responsible for the identification, development, and implementation of global human resource strategies. She provides guidance to the Medicago Executive team, defining and transitioning internal client groups towards process improvement, increased outcome and customer service orientation, and cost-effectiveness.
Prior, Lorrie held the positions of Head of Human Resources and Facilities for Kinapse Inc, CHRO for Carecentrix and Vice President of HR at PAREXEL International. Lorrie is certified nationally as GPHR and SCP through SHRM and CCP for World at Work. A magna cum laude graduate, she holds a BS in International Business from Franklin Piece University in Rindge, NH. Beyond to her corporate role, Lorrie is a Professor at Northeastern University where she has taught a variety of undergraduate classes and the SHRM certification prep class since 1999.
Vice-President, Commercial Operations
Nicolas is responsible for Sales & Marketing, Business Development, External Communications and External Affairs.
He joined Medicago in 2017 as Senior Director of Marketing.
Prior to joining Medicago, Nicolas worked for Sanofi for 10 years; based in 5 different countries in Europe, Asia and Eurasia; and gained experience in a large span of commercial functions including sales & marketing, launch readiness, business development and operational excellence.
Nicolas earned a Master of international management and a degree of Engineer in agronomy.
Brian J. Ward
Dr. Brian Ward is passionate about science and innovation. He has active research interests in RNA viruses, vaccine development and international health supported by Canadian and international funding agencies as well as private foundations and industry.
He is a Professor of Medicine and Microbiology at McGill University and serves on several national and international advisory committees in the areas of vaccine use, vaccine safety and international health.
Vice President, Research & Development
Dr. Marc-André D'Aoust is a pioneer of Medicago and joined the company at the beginning in 1999. Passionate about science and innovation, he has, over the years, led the development of the plant-based Proficia® technology, the virus-like particle (VLP) vaccine technology and the VLPExpress® high-throughput discovery platform of the company.
As Vice President Research & Development, he advances Medicago's technological vision and is responsible for the discovery, the development and the protection of the technological assets of the company. He is co-inventor on more than 700 patents and patent applications related to the platform or the products of the company. He studied plant biochemistry and molecular biology at Laval University where he received his Ph.D. in 2000.
Chief Safety Officer and Vice President Global Safety & Pharmacovigilance
Asif Mahmood, M.D., M.P.H., M.B.A., has served as our Chief Safety Officer/Vice President Global Safety & Pharmacovigilance since July 2019. Prior to joining Medicago, Asif Mahmood held several roles of increasing responsibility from Director to Associate Vice President at Pfizer, Sanofi, Genzyme, Sanofi Pasteur and Apotex in the US and Canada from 2004 to 2019.
He has experience of working on many diverse therapeutic areas including Vaccines, hepatology, oncology, infectious diseases, rare diseases, biosimilars, drug delivery devices, generics, and OTC.
Earlier in his career, he served as the Deputy Director General, Federal Ministry of Health in Islamabad, Pakistan, and as Medical Director and Joint Executive Director for Pakistan Institute of Medical Sciences and Children's hospital Islamabad. He has also served on many public health and immunization projects of WHO, UNICEF and Japan International Corporation Agency. He received his M.D., from King Edwards Medical University in Pakistan, in addition to completing M.P.H and M.B.A.
Where we work
North American roots with global ambitions.
Quebec | Canada
Medicago's history and head office are based in Quebec City, Canada where the research, product development, process development, and management functions are located. We have a 2,300m2 cGMP pilot production facility and a 1,300m2 greenhouse that meets strict confinement standards.
Medicago is currently building a new multi-million dollar complex in Quebec that will support our growing workforce and commercial production. The new facility will increase our production and research capacity for future projects such as pandemic flu, new vaccines, monoclonal antibodies, and other protein-based therapeutics.Learn more about life at
North Carolina | USA
Medicago USA, a wholly-owned subsidiary, is located in the Research Triangle Park (RTP) in North Carolina. Medicago USA's operations started in 2010 through a partnership with the U.S. Defense Advanced Research Projects Agency (DARPA). Our complex in RTP includes a 10,000m2 cGMP facility with a fully automated greenhouse and a state-of-the-art extraction and purification unit.Learn more about life
at Medicago USA
Collaboration has long been a driver of our success.
When it comes to addressing global health challenges, it's impossible to go at it alone. Medicago's technological and clinical accomplishments have been possible in large part thanks to the long-time, meaningful partnerships we've established with some of the leading educational institutions, researchers, and government agencies.